Jatamansi: Benefits, Evidence, Dosage & Safety

TL;DR

Jatamansi (Nardostachys jatamansi) rhizome is an Ayurvedic sedative traditionally used for insomnia. One small open-label trial (n=30) found 4 g of powder three times daily for a month improved sleep-initiation and sleep-duration scores, with no placebo comparison. No dedicated human safety trials exist; avoid in pregnancy. Evidence is thin: treat claims cautiously.

(53 words. Sources: Toolika et al., comparative clinical study; Singh et al., botanical standardization; Uddin et al., safety study.)

What it is

Jatamansi is the rhizome (underground stem) of Nardostachys jatamansi DC., an aromatic plant traditionally placed in the Valerianaceae family and known in English as spikenard (PMC review of its CNS pharmacology). It is an official drug in the Ayurvedic Pharmacopoeia of India (Part I, Volume III) (classical review citing API). Buyers should know it is frequently confused with two other plants sold under similar names: Valeriana wallichii ("Indian valerian") and Selinum vaginatum ("bhutkeshi"): botanical standardization work documents significant macro- and microscopic differences between the three (Singh et al., Indian Journal of Traditional Knowledge). Its major reported constituents are sesquiterpenes (including jatamansone, nardostachone, and valeranone) and coumarins (PMC review).

Traditional use

Classical Ayurvedic literature counts jatamansi among the nidrajanana (sedative and hypnotic) drugs, and it is an ingredient of formulations such as Mamsyadi Kwatha used for sleep disorders (insomnia trial, AYU). The Ayurvedic Pharmacopoeia of India recommends its rhizomes in skin diseases, cellulitis, disturbed mental states, and insomnia, and the tradition also records its use for depressive illness, convulsive conditions, palpitation of the heart, intestinal colic, high blood pressure, and dysmenorrhea (PMC review). A classical review notes the API describes it as nidrajanana and the older texts place it among the medhya (mind-supporting) drugs, with traditional rhizome-powder doses of 1–3 g (classical review). These are traditional claims, not clinical proof: the human-trial evidence is assessed separately below.

What modern research says

Sleep (primary insomnia)

The only human trial identified is a small open-label comparative study from an Ayurveda college hospital. Thirty-four patients with primary insomnia were allocated into two groups (30 completed, 15 per group): one received jatamansi churna (rhizome powder) 4 g with milk three times daily after food for one month. The other received tagara (Valeriana wallichii) powder on the same regimen. The jatamansi group showed statistically significant improvements from baseline in sleep initiation (61.34%), sleep duration (48.25%), disturbed sleep (53.08%), and disturbances in routine work (43.85%), all P<0.001 (Toolika et al., AYU).

Read the fine print: there was no placebo group and no blinding, so expectation effects cannot be ruled out. Between-group comparisons were mostly non-significant (tagara performed somewhat better); the paper reports no adverse-event data; and sleep was scored on a symptom scale rather than objective measures. This is a weak signal from one small trial: not proof that jatamansi treats insomnia.

Anxiety, depression, and other effects

No clinical trials of jatamansi for anxiety, depression, epilepsy, or blood pressure were identified. The reputation in these areas rests on animal and laboratory work: a rat/mouse study of crude rhizome powder reported CNS-depressant activity (reduced spontaneous motor activity, potentiation of pentobarbital-induced sleep) (PMC study). The insomnia trial's authors discuss a proposed GABA-related mechanism via valeranone and valepotriates, drawn from the phytochemistry literature rather than demonstrated in humans (Toolika et al.). Preclinical findings are hypotheses, not established effects in people.

What the evidence does not support (yet)

Beyond the single small insomnia study, there is no human-trial evidence that jatamansi helps anxiety, depression, seizures, hypertension, or skin disease. Traditional use in those areas is not clinical proof.

Dosage

There is no established modern dose. The single human trial used 4 g of jatamansi rhizome powder with milk, three times daily after food, for one month: a research regimen, not a personal recommendation (Toolika et al.). Classical reviews cite 1–3 g of rhizome powder as the traditional dose (classical review). Do not assume retail products match either preparation, and do not self-dose from these figures.

Safety & contraindications

The honest summary: no dedicated human safety trials of jatamansi were identified, and no NCCIH safety monograph exists for it. The insomnia trial did not report adverse-event data (Toolika et al.). A 2025 laboratory safety study of crude jatamansi drug tested for contaminants (heavy metals, aflatoxins, pesticide residues, microbes) and found them within WHO permissible limits: that speaks to raw-material quality, not to clinical safety in humans (Uddin et al., Hippocratic Journal of Unani Medicine). With no human safety data, avoid use in pregnancy and breastfeeding, and discuss it with a qualified clinician before use: especially if you take sedatives or other CNS-active medicines.

FAQs

Does jatamansi help with sleep?

Maybe, but the evidence is very thin. One small open-label study (30 patients, no placebo) found 4 g of rhizome powder three times daily for a month improved insomnia symptom scores (Toolika et al.). That is a weak signal, not proof.

Is jatamansi the same as valerian?

No. Jatamansi (Nardostachys jatamansi) is a distinct species and an official API drug. Valeriana wallichii is "Indian valerian" and Selinum vaginatum is "bhutkeshi." The three are botanically distinct and are sometimes confused in trade (Singh et al.).

What dose of jatamansi was studied?

The single human trial used 4 g of rhizome powder with milk, three times daily after food, for one month (Toolika et al.). Classical reviews cite a traditional dose of 1–3 g of rhizome powder (classical review). Neither is a recommendation.

Is jatamansi safe?

No dedicated human safety trials exist, and the one clinical study did not report adverse events (Toolika et al.). A laboratory study found contaminant levels within WHO limits (Uddin et al.). Treat it as an herb with unknown human safety: talk to a clinician first.

Can I take jatamansi during pregnancy?

Avoid it. There are no human safety data in pregnancy, and traditional sedative herbs should not be assumed safe. Discuss any use with your clinician.

Does jatamansi help with anxiety or depression?

No clinical trials were identified for anxiety or depression. Traditional use and animal studies suggest CNS-depressant activity, but that is not human proof (PMC study).

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.